person · Reporting owner

Gulfo Adele M.

Disclosed activity across 5 companies

Tapewire entity: 36908
SEC CIK: 0001647102

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Enpro Inc.NPO · Entity 3782	Director	September 16, 2026	September 17, 2026
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	January 07, 2026	January 10, 2026
Tyra Biosciences, Inc.TYRA · Entity 4680	Director	May 28, 2026	June 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Enpro Inc.

Report date September 16, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	5,281.7774	Reported balance After 2026-09-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-16 · Grant · Acquired 5 · Balance 5,281.7774 F1: 1-for-1 F2: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents.
Phantom StockSEC Table II · derivative / convertible security	Direct	5,282.351	Reported balance After 2026-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-16 · Grant · Acquired 0.5736 · Balance 5,282.351 F1: 1-for-1 F5: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents.

Filing footnotes · ownership attribution and instrument terms

F1: 1-for-1

F2: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc.

F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate.

F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents.

F5: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc.

NewAmsterdam Pharma Co N.V.

Report date January 07, 2026 · Filed January 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	14,260	Reported balance After 2026-01-07 transaction · row 1 1 source row Row 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 14,260 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07	Direct	15,300	Reported balance After 2026-01-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

F2: Each RSU was granted on January 7, 2026 for no consideration.

F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Tyra Biosciences, Inc.

Report date May 28, 2026 · Filed June 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27	Direct	13,160	Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BEMIS CO INC

Report date June 11, 2019 · Filed June 11, 2019

Section 16 reporting ended · disclosed 2019-06-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-06-11 transaction · row 1 1 source row Row 1 · 2019-06-11 · Disposition to issuer · Disposed 12,383 · Balance 0 F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc. F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc.

F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit.

F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares).

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-03-10 transaction · row 1 1 source row Row 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2030-02-23	Direct	Reported balance After 2023-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14	Direct	Reported balance After 2023-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04	Direct	Reported balance After 2023-03-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.

F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").

F4: These options are fully vested.

F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2026 Filed Sep 17, 2026 22:08 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.5736	$287.16	$164.71	Disclosure SEC source: 0001225208-26-007864 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,282.351 Underlying: Common Stock · 0.5736 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 16, 2026 Filed Sep 17, 2026 22:08 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	5	$287.16	$1,435.80	Disclosure SEC source: 0001225208-26-007864 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,281.7774 Underlying: Common Stock · 5 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 17, 2026 Filed Jun 18, 2026 18:48 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.4526	$363.62	$164.57	Disclosure SEC source: 0001225208-26-006114 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,276.7774 Underlying: Common Stock · 0.4526 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 17, 2026 Filed Jun 18, 2026 18:48 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	4	$363.62	$1,454.48	Disclosure SEC source: 0001225208-26-006114 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,276.3248 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	GrantStock Option (Right to Buy) · Derivative	13,160	$0.00 Strike: $32.68	$0.00	Disclosure SEC source: 0001193125-26-251536 · ownership.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,160 Underlying: Common Stock · 13,160 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document
March 18, 2026 Filed Mar 19, 2026 18:47 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.6559	$250.59	$164.36	Disclosure SEC source: 0001225208-26-003857 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,272.3248 Underlying: Common Stock · 0.6559 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 18, 2026 Filed Mar 19, 2026 18:47 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	5	$250.59	$1,252.95	Disclosure SEC source: 0001225208-26-003857 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,271.6689 Underlying: Common Stock · 5 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 12, 2026 Filed Feb 12, 2026 22:51 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	567	$246.91	$139,997.97	Disclosure SEC source: 0001225208-26-001823 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,860 F1 · kind: Shares acquired pursuant to the Enpro Inc. 2020 Equity Compensation Plan (as amended and restated). Read SEC document
January 07, 2026 Filed Jan 10, 2026 00:34 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	15,300	$0.00 Strike: $35.45	$0.00	Disclosure SEC source: 0001193125-26-009273 · ownership.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Ordinary Shares · 15,300 shares Expires 2036-01-07 F3 · derivative.exercise_date: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Read SEC document
January 07, 2026 Filed Jan 10, 2026 00:34 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	3,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-009273 · ownership.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,260 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document
December 31, 2025 Filed Jan 5, 2026 18:29 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	116.7515	$214.13	$25,000.00	Disclosure SEC source: 0001225208-26-000117 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,266.6689 Underlying: Common Stock · 116.7515 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
December 17, 2025 Filed Dec 18, 2025 18:59 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.5988	$205.19	$122.87	Disclosure SEC source: 0001225208-25-010134 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,149.9174 Underlying: Common Stock · 0.5988 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
December 17, 2025 Filed Dec 18, 2025 18:59 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	6	$205.19	$1,231.14	Disclosure SEC source: 0001225208-25-010134 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,149.3186 Underlying: Common Stock · 6 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 30, 2025 Filed Oct 1, 2025 19:02 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	110.6195	$226.00	$25,000.01	Disclosure SEC source: 0001225208-25-008171 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,143.3186 Underlying: Common Stock · 110.6195 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
September 17, 2025 Filed Sep 18, 2025 18:19 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.4059	$217.89	$88.44	Disclosure SEC source: 0001225208-25-008054 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,032.6991 Underlying: Common Stock · 0.4059 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 17, 2025 Filed Sep 18, 2025 18:19 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	6	$217.89	$1,307.34	Disclosure SEC source: 0001225208-25-008054 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,032.2932 Underlying: Common Stock · 6 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 30, 2025 Filed Jul 1, 2025 18:12 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	130.5142	$191.55	$25,000.00	Disclosure SEC source: 0001225208-25-006229 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,026.2932 Underlying: Common Stock · 130.5142 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
June 18, 2025 Filed Jun 20, 2025 18:13 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	0.2577	$185.86	$47.90	Disclosure SEC source: 0001225208-25-006068 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,895.779 Underlying: Common Stock · 0.2577 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F5 · kind: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 18, 2025 Filed Jun 20, 2025 18:13 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	7	$185.86	$1,301.02	Disclosure SEC source: 0001225208-25-006068 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,895.5213 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
April 15, 2025 Filed Apr 17, 2025 21:36 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	50,700	$0.00 Strike: $16.06	$0.00	Disclosure SEC source: 0000950170-25-055603 · ownership.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,700 Underlying: Ordinary Shares · 50,700 shares Expires 2035-04-15 F3 · derivative.exercise_date: 33% of the shares underlying the option will vest on April 15, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date. Read SEC document
April 15, 2025 Filed Apr 17, 2025 21:36 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	10,860	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-055603 · ownership.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,860 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on April 15, 2025 for no consideration. Read SEC document
March 31, 2025 Filed Apr 1, 2025 18:50 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	154.5213	$161.79	$25,000.00	Disclosure SEC source: 0001225208-25-003759 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,888.5213 Underlying: Common Stock · 154.5213 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Share units acquired under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document
March 19, 2025 Filed Mar 20, 2025 18:21 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	7	$175.76	$1,230.32	Disclosure SEC source: 0001225208-25-003523 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,734 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 13, 2025 Filed Feb 13, 2025 20:41 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	685	$182.27	$124,854.95	Disclosure SEC source: 0001225208-25-001645 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,727 Underlying: Common Stock · 685 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. F3 · derivative.exercise_date: The reporting person elected to defer receipt of shares underlying the award. In accordance with his/her deferral election, the shares will be delivered to the reporting person in one lump sum upon Separation from Service. F3 · derivative.expiration_date: The reporting person elected to defer receipt of shares underlying the award. In accordance with his/her deferral election, the shares will be delivered to the reporting person in one lump sum upon Separation from Service. Read SEC document
January 29, 2025 Filed Jan 31, 2025 21:10 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	GrantCommon Stock (Right to Buy) · Derivative	37,200	$0.00 Strike: $14.65	$0.00	Disclosure SEC source: 0000950170-25-011737 · ownership.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2035-01-28 F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following January 29, 2025, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document
December 18, 2024 Filed Dec 19, 2024 18:20 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	7	$175.86	$1,231.02	Disclosure SEC source: 0001225208-24-010927 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,042 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 18, 2024 Filed Sep 19, 2024 20:48 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	8	$156.77	$1,254.16	Disclosure SEC source: 0001225208-24-008776 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,035 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 20, 2024 Filed Jun 24, 2024 19:35 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	8	$146.91	$1,175.28	Disclosure SEC source: 0001225208-24-006983 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,027 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 20, 2024 Filed Mar 21, 2024 20:12 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	8	$159.77	$1,278.16	Disclosure SEC source: 0001225208-24-004383 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,019 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 15, 2024 Filed Feb 15, 2024 21:37 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	803	$155.66	$124,994.98	Disclosure SEC source: 0001225208-24-002154 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,293 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
December 13, 2023 Filed Dec 14, 2023 21:36 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	8	$140.49	$1,123.92	Disclosure SEC source: 0001225208-23-011126 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,011 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
September 13, 2023 Filed Sep 14, 2023 20:09 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	9	$123.90	$1,115.10	Disclosure SEC source: 0001225208-23-008930 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,003 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 14, 2023 Filed Jun 15, 2023 21:11 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	9	$125.72	$1,131.48	Disclosure SEC source: 0001225208-23-006863 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,994 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 15, 2023 Filed Mar 16, 2023 20:38 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	12	$95.94	$1,151.28	Disclosure SEC source: 0001225208-23-004003 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 12 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	21,096	Not disclosed Strike: $22.71	Not disclosed	Disclosure SEC source: 0001209191-23-017718 · doc4.xml · derivative · entry 4 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	21,603	Not disclosed Strike: $21.47	Not disclosed	Disclosure SEC source: 0001209191-23-017718 · doc4.xml · derivative · entry 3 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	45,000	Not disclosed Strike: $11.17	Not disclosed	Disclosure SEC source: 0001209191-23-017718 · doc4.xml · derivative · entry 2 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2030-02-23 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerCommon Shares	3,673	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-017718 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · shares: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3 · price: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). Read SEC document
February 16, 2023 Filed Feb 17, 2023 17:26 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	942	$116.69	$109,921.98	Disclosure SEC source: 0001225208-23-002193 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,490 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
December 14, 2022 Filed Dec 15, 2022 20:27 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	10	$107.94	$1,079.40	Disclosure SEC source: 0001225208-22-012820 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
October 26, 2022 Filed Oct 28, 2022 20:38 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantCommon Shares	9,859	$0.00	$0.00	Disclosure SEC source: 0001209191-22-054814 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,859 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time. F2 · shares: Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement"). Read SEC document
September 14, 2022 Filed Sep 15, 2022 19:14 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	12	$90.25	$1,083.00	Disclosure SEC source: 0001225208-22-010340 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963 Underlying: Common Stock · 12 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 15, 2022 Filed Jun 16, 2022 18:28 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	13	$87.50	$1,137.50	Disclosure SEC source: 0001225208-22-008155 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,951 Underlying: Common Stock · 13 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 16, 2022 Filed Mar 17, 2022 19:59 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	10	$106.51	$1,065.10	Disclosure SEC source: 0001225208-22-004827 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
February 15, 2022 Filed Feb 16, 2022 19:13 UTC	Enpro Inc. NPO · Entity 3782	GrantCommon Stock	1,041	$105.64	$109,971.24	Disclosure SEC source: 0001225208-22-002246 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,548 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document
December 15, 2021 Filed Dec 16, 2021 22:19 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	10	$106.21	$1,062.10	Disclosure SEC source: 0001225208-21-015068 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,928 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
November 05, 2021 Filed Nov 9, 2021 22:36 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	21,096	$0.00 Strike: $22.71	$0.00	Disclosure SEC source: 0001209191-21-063676 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,096 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) November 5, 2022, and (b) the date that is one day prior to the Issuer's 2022 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
September 15, 2021 Filed Sep 17, 2021 20:06 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	13	$82.96	$1,078.48	Disclosure SEC source: 0001225208-21-012454 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,918 Underlying: Common Stock · 13 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
June 16, 2021 Filed Jun 17, 2021 19:43 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	11	$98.35	$1,081.85	Disclosure SEC source: 0001225208-21-009499 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,905 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document
March 17, 2021 Filed Mar 18, 2021 20:17 UTC	Enpro Inc. NPO · Entity 3782	GrantPhantom Stock · Derivative	11	$91.41	$1,005.51	Disclosure SEC source: 0001225208-21-005584 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,894 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.